Hutchmed has announced the initiation of a Phase I clinical trial of its menin inhibitor, HMPL-506, to potentially treat patients with haematological malignancies in China.

The first subject received the initial dose of the treatment on 31 May.

This multicentre, open-label study is designed to assess the pharmacokinetics, safety, and efficacy of HMPL-506 when administered orally to patients with haematological malignancies.  

Aiming to enrol 60 to 98 patients, the study will proceed through two phases: a dose escalation phase followed by a dose expansion phase.

Eligibility for the study is contingent upon patients providing signed informed consent.

The dose escalation phase will include approximately 30 to 38 patients with mixed-lineage leukaemia (MLL)-rearranged and/or NPM1-mutant relapsed/refractory acute myeloid leukaemia (AML) and acute lymphocytic leukaemia (ALL).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This phase will utilise an accelerated titration design with the modified toxicity probability interval-2 (mTPI-2) design for dose escalation and establishing the maximum tolerated dose (MTD).

Following the establishment of the recommended Phase II dose (RP2D) and/or MTD, the dose expansion phase will commence.

This phase will enrol 30 to 60 patients to further evaluate the safety, tolerability, and preliminary efficacy of HMPL-506.

Currently, there are no menin inhibitors approved globally.

HUTCHMED retains the complete rights to HMPL-506 across the globe.

The latest development comes after the company commenced a Phase II/III clinical trial of surufatinib in combination with other drugs as a first-line therapy for metastatic pancreatic ductal adenocarcinoma (PDAC) in China.

This treatment regimen includes surufatinib alongside camrelizumab from Jiangsu Hengrui Pharmaceuticals, as well as nab-paclitaxel and gemcitabine.

The first patient in the trial received their first dose on 8 May.